3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Conditions
Carcinoma, Hepatocellular
42
Parkinson Disease 4, Autosomal Dominant Lewy Body
29
Carcinoma, Renal Cell
26
Endometrial Neoplasms
13
Melanoma
10
Neoplasms
8
Uterine Cervical Neoplasms
7
Cholangiocarcinoma
7
Biliary Tract Neoplasms
7
Liver Neoplasms
6
Stomach Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Neuroendocrine Tumors
5
Triple Negative Breast Neoplasms
4
Thyroid Neoplasms
4
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Esophageal Squamous Cell Carcinoma
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Thyroid Carcinoma, Anaplastic
3
Recurrence
3
Kidney Neoplasms
3
Esophageal Neoplasms
3
Diabetes Mellitus, Insulin-Dependent, 12
3
Carcinoma, Adenoid Cystic
3
Breast Neoplasms
3
Brain Neoplasms
3
Adenocarcinoma
3
Vulvar Neoplasms
2
Interventions
pembrolizumab
4
aldesleukin
3
Cisplatin
3
lenvatinib
2
Surveys and Questionnaires
2
Specimen Handling
2
Paclitaxel
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Adoptive Transfer
2
zimberelimab
1
trastuzumab deruxtecan
1
tivozanib
1
liposomal doxorubicin
1
fludarabine phosphate
1
fludarabine
1
entinostat
1
dostarlimab
1
cemiplimab
1
bintrafusp alfa protein, human
1
belzutifan
1
atezolizumab
1
Therapeutic Touch
1
Taxes
1
Standard of Care
1
Sonazoid
1
Respiratory Function Tests
1
Radiotherapy
1
Radiation
1
Prochlorperazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Vulvar Neoplasms
×
lenvatinib
×
1 year
×
Clear all
NCT05903833
2026-05-11
PIERCE
AGO Research GmbH
Phase 2
Recruiting
42 enrolled
NCT07290894
2026-04-02
MITO VULVA-01
National Cancer Institute, Naples
Phase 2
Recruiting
80 enrolled